UY27275A1 - Composiciones y metodos para aumentar la biodisponibilidad de agentes farmacéuticos - Google Patents

Composiciones y metodos para aumentar la biodisponibilidad de agentes farmacéuticos

Info

Publication number
UY27275A1
UY27275A1 UY27275A UY27275A UY27275A1 UY 27275 A1 UY27275 A1 UY 27275A1 UY 27275 A UY27275 A UY 27275A UY 27275 A UY27275 A UY 27275A UY 27275 A1 UY27275 A1 UY 27275A1
Authority
UY
Uruguay
Prior art keywords
biodisponibility
compositions
methods
increase
pharmaceutical agents
Prior art date
Application number
UY27275A
Other languages
English (en)
Inventor
Hing L Sham
Elizabeth A Everitt
Dale J Kempf
Edward K Han
Sajeev P Cherian
Shi-Chung Ng
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of UY27275A1 publication Critical patent/UY27275A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Esta invención se relaciona con el aumento de la biodisponibilidad de agentes farmacéuticamente activos. En particular, se relaciona con el uso de lopinavir, sus equivalentes aceptables para uso farmacéutico y derivados del mismo como inhibidores de la glicoproteina P.
UY27275A 2001-05-01 2002-04-30 Composiciones y metodos para aumentar la biodisponibilidad de agentes farmacéuticos UY27275A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36735301P 2001-05-01 2001-05-01

Publications (1)

Publication Number Publication Date
UY27275A1 true UY27275A1 (es) 2002-11-29

Family

ID=23446823

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27275A UY27275A1 (es) 2001-05-01 2002-04-30 Composiciones y metodos para aumentar la biodisponibilidad de agentes farmacéuticos

Country Status (10)

Country Link
US (1) US20020198160A1 (es)
EP (1) EP1387684A1 (es)
JP (1) JP2005511481A (es)
AR (1) AR033293A1 (es)
CA (1) CA2445967A1 (es)
MX (1) MXPA03010054A (es)
PE (1) PE20021075A1 (es)
TW (1) TWI231211B (es)
UY (1) UY27275A1 (es)
WO (1) WO2002087585A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
AU2005216712A1 (en) * 2004-01-30 2005-09-09 Pfizer Inc. Compositions comprising HIV protease inhibitor and cytochrome P450 enzyme activity inhibitor
US7385084B2 (en) * 2004-06-23 2008-06-10 Synta Pharmaceutical Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
US8017654B2 (en) * 2005-04-15 2011-09-13 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
RU2433822C2 (ru) 2005-08-16 2011-11-20 Синта Фармасьютиклз Корп. Композиция бис(тио-гидразид амида)
JP2010501562A (ja) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
EP2076254A2 (en) * 2006-08-31 2009-07-08 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
TW200829543A (en) * 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
SI2451445T1 (sl) 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
JP2013536244A (ja) * 2010-08-26 2013-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇｆｒ阻害剤の投与方法
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
JP2005511481A (ja) 2005-04-28
US20020198160A1 (en) 2002-12-26
MXPA03010054A (es) 2004-04-02
PE20021075A1 (es) 2002-12-07
TWI231211B (en) 2005-04-21
CA2445967A1 (en) 2002-11-07
EP1387684A1 (en) 2004-02-11
WO2002087585A1 (en) 2002-11-07
AR033293A1 (es) 2003-12-10

Similar Documents

Publication Publication Date Title
UY27275A1 (es) Composiciones y metodos para aumentar la biodisponibilidad de agentes farmacéuticos
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
ATE468332T1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
BR112016008016A2 (pt) inibidores de kras g12c
GT200500363A (es) 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento.
UY29238A1 (es) Formulaciones de nepafenac para su administracion topica
CY1109117T1 (el) Διαμορφωσεις enaιωphmatoς, οι οποιες περιλαμβανουν δραστικον συστατικο, επιφανειακως δρωσαν ουσια poloxamer ή meroxapol και γλυκολη, χρησις του δια την βιομηχανικην παρασκευην φαρμακου προς νοσηλειαν οφθαλμικων διαταραχων
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
BRPI0513841A (pt) composto, composição farmacêutica, e uso do composto
SV2008001369A (es) Benzimidazoles
BR112015018087A8 (pt) composto, composição farmacêutica e uso
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
EA200870545A1 (ru) Новые гетероциклические соединения
UY28906A1 (es) Derivados de pirimidina que son antagonistas del receptor vitronectina
CY1108676T1 (el) Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων
FR2873585B1 (fr) Nouvelles formulations galeniques de principes actifs
IS8051A (is) Kladríbínefnablöndur til inngjafar um munn
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141125